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Abstract
Purpose: Hydrogel prostate-rectum spacers, biomaterials placed between the prostate and rectum,
continue to gain interest as a method to reduce or limit rectal dose during dose escalated prostate cancer
radiation therapy. Because the spacer is initially injected into the perirectal space as a liquid, the final
distribution can vary. The purpose of this study was to evaluate hydrogel spacer (SpaceOAR system)
implantation and distribution from a recent prospective randomized control trial and correlate spacer
symmetry with rectal dose reduction as well as rectal wall infiltration (RWI) to acute and late toxicity.
Methods and materials: T2-weighted magnetic resonance imaging sets of 149 patients enrolled in a
prospective clinical trial who received transperineal spacer injection were assessed for hydrogel spacer
midline symmetry and RWI using a semiqualitative scoring system. Symmetry was then correlated to
rectal dose reduction using a Student t test (1-tailed, paired), whereas a Fisher exact test was used to
correlate RWI with acute and late rectal toxicity. All patients had control treatment plans created before
spacer injection.
Results: Hydrogel spacer was symmetrically placed at midline for 71 (47.7%) patients at the prostate
midgland as well as 1 cm superior and inferior to midgland. The remaining 78 (50.9%) patients had some
level of asymmetry, with only 2 (1.3%) having far lateral distribution (ie, N2 cm) of hydrogel spacer. As
the hydrogel spacer became more asymmetric, the level of rectal dose reduction relative to their control
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plans decreased. However, all but the most asymmetrical 1.3% had significant rectal dose reduction (P b
.05). Rectal wall hydrogel spacer infiltration was seen in 9 (6.0%) patients. There was no correlation
between RWI and procedure-related adverse events or acute/late rectal toxicity.
Conclusions: Significant reduction of rectal dose can still be achieved even in the setting of asymmetric
hydrogel spacer placement. RWI does not correlate with patient complications.
© 2016 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
Introduction
Multiple randomized controlled trials have demonstrated
that dose escalated radiation therapy (RT) for prostate cancer
results in improved clinical outcomes, including local control,
progression-free survival, and distant metastases-free
survival.1-4 However, despite improved outcomes, dose
escalation is associated with increased gastrointestinal and
rectal toxicity.1 Although recent advances in radiation
technology and/or delivery, including image guided radiation
therapy (IGRT) and intensity modulated RT (IMRT), have
reduced toxicity, it remains difficult to spare the anterior wall
of the rectum. Interest has grown in biomaterials that can be
injected between the prostate and rectum to allow for a
separation that can ultimately reduce rectal dose for patients
receiving external beam RT.5 As previously described in the
literature, these biomaterial prostate-rectum spacers can
include hyaluronic acid, collagen, absorbable balloons, and
polyethylene glycol (PEG) hydrogels.6-11
PEG hydrogels, specifically, have been the most widely
studied and used biomaterial for perirectal spacing. They
are primarily composed of water and cross-linked PEG and
are injected into the anterior perirectal space/fat as a thin
liquid. Once within the perirectal space, they then
immediately polymerize into a soft hydrogel that is
tissue-dense on computed tomography (CT) and hyperin-
tense on T2-weighted magnetic resonance imaging (MRI).
After approximately 3 months, the hydrogel begins to
hydrolyze and eventually is cleared via renal filtration.
A recent multicenter randomized controlled trial
studying a PEG hydrogel demonstrated a 98.7% hydrogel
placement success rate, an average of 1.26 cm of perirectal
spacing, a 73.3% relative reduction in the rectal volume
receiving at least 70 Gy (rV70), and significant improve-
ments in late rectal toxicity and bowel quality of life.12
Although prior publications have evaluated application
technique, patient safety and tolerance, dosimetric effects,
and clinical outcomes for participants of the US Pivotal
Trial as described previously, neither the distribution of
the hydrogel nor hydrogel rectal wall infiltration (RWI)
has been analyzed. The purpose of this secondary
analysis of the SpaceOAR US Pivotal trial was to assess
hydrogel distribution and its impact on rectal dose
reduction as well as the rate of rectal wall infiltration
and its impact on rectal toxicity.
Methods and materials
Setting and patients
All patients provided written informed consent and were
enrolled in a multicenter randomized controlled trial of
hydrogel spacer placement that was approved by the
institutional review boards of all 20 participating centers
under the US Food and Drug Administration–approved
investigational device exemption. Inclusion and exclusion
criteria were described previously.10 Menwith stage T1 or T2
prostate cancer, Gleason score≤7, a prostate-specific antigen
concentration ≤20 ng/mL, and Zubrod performance status 0
to 1 who were planning to receive IG-IMRT were potential
study candidates.
In total, 149 patients included in the study were
randomized to receive the hydrogel spacer (SpaceOAR
System, Augmenix, Inc., Waltham, MA) before IG-IMRT.
Patients received a preimplantation CT scan and
T2-weighted MRI simulation for baseline treatment
planning purposes. They were then placed in the dorsal
lithotomy position. Using an aseptic, transperineal tech-
nique, 3 gold intraprostate fiducial markers were placed
followed by transperineal injection of the spacer into the
anterior perirectal space between Denonvilliers’ fascia and
the anterior rectal wall. Markers and hydrogel spacer were
injected under transrectal ultrasound guidance with
general anesthesia, local anesthesia, or monitored anes-
thesia care. Within 5 to 10 days of hydrogel spacer
placement, patients received a repeat postprocedural CT
scan and T2-weighted MRI simulation for treatment
planning.
Each patient had plans created on both the baseline and
postprocedural simulations to determine rectal dose
reduction resulting from the hydrogel spacer. The clinical
target volume (CTV) included the entire prostate with or
without the inclusion of the seminal vesicles, at the
discretion of the treating physician.10 Planning target
volumes (PTV) were a 5- to 10-mm expansion of the CTV,
also at the discretion of the treatment physician. The CTV
and PTV margins did not vary between control and
postinjection plans. The prescription dose was 79.2 Gy at
1.8 Gy fractions delivered to ≥98% of the PTV and 100%
of the CTV. Normal rectal dose constraint objectives were
per the Quantitative Analysis of Normal Tissue Effects in
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the Clinic guidelines.13 The planning methodology for
baseline and postprocedural plans was the same. All plans
were reviewed by a blinded, independent core laboratory
for verification of the target volume contours, critical
normal structure contours, dosimetric data, measurement
of the perirectal space, and success of hydrogel placement.
Patients were evaluated at baseline, weekly during
IG-IMRT, and at 3-, 6-, 12-, and 15-month follow-up visits
for adverse events as well as for changes in medications for
both urinary and rectal symptoms. An independent
Clinical Events Committee, blinded to treatment random-
ization, evaluated all adverse events, and related them to
device, procedure, radiation, or other causes. All adverse
events attributed to radiation by the Clinical Events
Committee were included for toxicity analysis per the
National Cancer Institute’s Common Terminology Criteria
for Adverse Events (CTCAE), version 4.0.
Distribution analysis
The posthydrogel implanted T2-weighted MRI for all
treated patients were used to evaluate hydrogel spacer
distribution. The hydrogel spacer is approximately 90%
water, resulting in a hyperintense T2-weighted MRI
signal. A team of 3 radiation oncologists evaluated the
postimplant T2-weighted MRI for all 149 patients and
determined hydrogel symmetry using a semiqualitative
scoring system, as seen in Table 1. As shown in Figure 1,
three axial slices were evaluated in every patient (the
midgland axial slice, 1 cm superior to midgland, and 1 cm
inferior to midgland). Table 1A contains the semiqualita-
tive scoring method used to score hydrogel symmetry on
every slice. Axial slices without hydrogel spacer received
a score of 0, slices with midline spacer symmetry received
a score of 1, and asymmetric lateral hydrogel distributions,
based on the medial aspect of the spacer, of 1 or 2 cm
received scores of 2 or 3, respectively. Figure 2 shows
representative images of symmetrical and asymmetrical
gel distribution. To obtain a single symmetry score per
patient, the scoring method outlined in Table 1B was used,
with a score of 1 being gel symmetry in all 3 slices and
scores 2 through 5 representing increasing hydrogel
asymmetry. The patient level symmetry score was then
compared with the pre and post hydrogel treatment plans
to determine the impact of spacer asymmetry on rectal
dose reduction. In addition to evaluation 1 cm above and
below midgland, the presence of hydrogel at the apex and
base of the prostate was also quantitatively evaluated.
The extent of hydrogel RWI was assessed for each patient
by the same radiation oncologists. Evaluating every axial
slice, the most extensive hydrogel RWI in each patient was
scored using the qualitative method outlined in Table 1C.
Scoring ranged from no rectal wall infiltration (0) to minimal
(1, small discrete areas), moderate (2, b25% of rectum
circumference), and significant (3, ≥25% of rectum circum-
ference) infiltration. Correlations of patient RWI score with
procedure-related adverse events and with acute and late
rectal toxicity (per CTCAE 4.0) were then determined.
Table 1 Hydrogel scoring methodology
(A) Axial slice hydrogel symmetry scoring method
Score Description
0 No hydrogel in slice
1 Hydrogel centered on prostate midline
2L, 2R 1 cm hydrogel asymmetry from midline, left, or right
3L, 3R N2 cm hydrogel asymmetry from midline, left, or right
(B) Patient-level symmetry scoring method
Score Description
Sym 1 All 3 slices with symmetrical distribution
Sym 2 1 of 3 slices with 1 cm lateral distribution
Sym 3 2 of 3 slices with 1 cm lateral distribution
Sym 4 All 3 slices 1 cm lateral or ≤2/3 slices 2 cm lateral distribution
Sym 5 All 3 slices with 2 cm lateral distribution
(C) RWI scoring method
RWI Description
0 No RWI
1 Minimal RWI (ie, small discrete areas of gel in wall)
2 Moderate RWI (ie, b25% rectal wall circumference)
3 Significant RWI (ie, ≥25% rectal wall circumference)
RWI, rectal wall infiltration.
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Statistical analysis
Student t test was used to evaluate the statistical
significance between the Sym 1 and other Sym groups
regarding rectal dose reduction and the difference between
pre- and postspacer rectal dose for each Sym group. The
Fisher exact test was used to determine the statistical
significance between hydrogel RWI and procedural
adverse events and with acute and late rectal toxicity. A
P value of b.05 was considered statistically significant,
and data analysis was performed using Excel 2013
(Microsoft Corporation, Redmond, WA) and SPSS Statis-
tics v.23 (IBM Corporation, Armonk, NY).
Results
Spacer symmetry analysis
PEG hydrogel was found in every axial MRI slice while
scoring hydrogel symmetry. Overall, a symmetrical spacer
application was found in 92 (62%) of the midgland and
superior axial slices, and in 108 (72%) of the inferior
slices, as shown in Figure 3A. On average, 24 (16%) and
26 (17%) of the axial slices had 1 cm lateral distribution
(left and right, respectively), with 2 (1.3%) and 1 (0.7%)
with ≥2 cm lateral distribution. There was no apparent
trend for left or right asymmetry. Regarding overall
Figure 2 T2-weighted magnetic resonance images of symmetrical hydrogel distribution (A, score = 1), 1 cm lateral distribution (B,
score = 2), and N2 cm lateral distribution (C, score = 3).
Figure 1 Coronal view of the prostate with location of the midgland, superior (Sup), and inferior (Inf) axial slices evaluated. Also
shown are symmetry locations, with 1 representing midline, 2L/2R representing 1 cm left and right, and 3L/3R 2 cm left and right,
respectively.
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symmetry per patient, 73 (49.0%) patients had spacer
symmetry in all 3 (midgland, 1 cm above and below) axial
slices (Sym score 1), with 26 (17.4%), 20 (13.4%), 28
(18.8%), and 2 (1.3%) patients with scores of Sym 2
through Sym 5, respectively. Hydrogel was present at both
the apex and base of the prostate in 48 (32%) of patients,
and was absent at either the apex and/or base in 101 (68%)
of patients.
When subtracting the postspacer from the prespacer
rectal dose-volume histograms (DVHs), a rectal dosimetric
benefit was observed in all groups. The rectal dose
reduction (prespacer to postspacer) for groups Sym score 1
through Sym score 4 was statistically significant for rV50
through rV80 (P b .0001). Figure 3B depicts the rectal
DVH and percentage of rectal volume that could be
anticipated to receive a specific dose as a function of Sym
score. The percent absolute dose reduction at rV50, rV60,
rV70, and rV80 for all Sym groups was 13.4%, 11.6%,
9.1%, and 3.9%, respectively. Sym scores 1/2 had lowest
percentage of rectal volume receiving each high dose
metric (i.e. rV50-85) followed by Sym scores 3/4. Sym
group 5 had the least reduction in rectal dose, which was
statistically inferior when compared with Sym scores 1-4
(P b .001). For all Sym groups, the mean relative dose
reduction at rV50, rV60, rV70, and rV80 was 52.4%,
63.5%, 73.5%, and 71.6%, respectively. The percent mean
relative dose reduction for each Sym group is depicted in
e-Figure 1 (available as supplementary material online
only at www.practicalradonc.org).
In total, 4 patients (2.7%) did not meet a≥25% reduction
in rV70Gy based on post- to prespacer DVH. This included
1 patient with Sym score 3 (absolute rV70Gy reduction =
5.1%), 2 patients with Sym score 4 (absolute rV70Gy
reduction = -27.6% and -3.2%%), and 1 patient with Sym
score 5 (absolute rV70Gy reduction = -37.7%). The 2
Table 2 Rates of hydrogel RWI and average rectal wall gel
volume
RWI score No. of
patients (%)
Average RW gel
volume (mL)
0 140 (94.0) 0.0
1 5 (3.4) 0.1
2 3 (2.0) 0.9
3 1 (0.7) 2.4
RWI, rectal wall infiltration.
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Figure 3 (A) Axial slice symmetry scores, per Table 1: Hydrogel symmetry was observed in 61.7% of midgland and superior axial
slices and in 71.8% of inferior slices. (B) Absolute rectal dose-volume histogram (DVH) for each Sym score group following spacer
application.
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(1.34%) patients with marked lateral (≥2 cm) distribution in
all 3 axial slices (Sym score 5) on average still had some
rectal dosimetric benefit relative to the prespacer rectal
DVH, although the difference between pre- and postspacer
plans was not significant (P N .05).
Spacer rectal wall infiltration analysis
As shown in Table 2, of the 149 spacer patients
evaluated, 140 (94.0%) had no gel within the rectal wall,
whereas 5 (3.4%), 3 (2.0%), and 1 (0.7%) had RWI scores
of 1, 2, and 3, respectively. The average hydrogel volumes
delineated in rectal walls was 0.1, 0.9, and 2.4 mL, for
RWI scores of 1, 2, and 3, respectively. Of the 149 spacer
treated patients, 15 (10%) had transient adverse events (eg,
anorectal pressure, perineal pain) following the spacer
application procedure.12 As seen in Table 3, 14 of those
events occurred in patients with no RWI, whereas 1 patient
with a urinary tract obstruction was in the RWI 1 group. A
total of 36 of the 140 patients with no rectal wall
infiltration had acute rectal toxicity (26%, maximum grade
2), compared with 3 of 5 (60%, maximum grade 1), and 1
of 3 (33%, maximum grade 1) of the RWI 1 and RWI 2
patients, respectively. In the entire study, there were only 3
(2.0%) patients with late rectal toxicity through 15 months
(all grade 1), 2 of which were in the RWI 0 group and 1 in
the RWI 1 group. There were no significant differences
between RWI rating and procedure-related events or acute/
late toxicity rates. The only patient with RWI 3 (gel in
≥25% rectal wall circumference) experienced no
procedure-related event and no acute or late rectal toxicity.
For those patients who did not meet a ≥25% reduction in
rV70Gy (4 patients), only 1 had RWI with a score of 1.
Figure 4 shows representative images of patients with the
different RWI scores.
Discussion
For patients receiving external beam RT for prostate
cancer, the volume of rectum receiving a high dose (ie,≥60
Gy) is consistently associated with the risk of ≥grade 2
rectal toxicity or rectal bleeding, based on CTCAE.13 There
has been significant interest in methods to reduce the high
dose to the anterior rectum, including modern delivery
techniques of RT (ie, IMRT or proton therapy) as well as
advanced imaging and target localization. One option
receiving growing interest has been the use of absorbable
balloons and biomaterials placed between the prostate and
rectum with the goal of separating these structures and
ultimately reducing rectal dose and toxicity.5 Some of these
biomaterials have included hyaluronic acid, collagen,
absorbable balloons, and PEG hydrogels.6-11 PEG hydrogel
is of particular interest given its stability during the course of
fractionated RT and its easy visualization on imaging. The
recent hydrogel spacer prospective, multicenter, randomized,
Table 3 RWI impact on procedure-related AEs, acute, and late toxicity
(A) Procedural AEs
RWI No. of patients (%) P value a Maximum CTCAE grade
0 14/140 (9.3) NA 3 b
1 1/5 (20) c .43 2
2 0/3 (0.0) 1.00 0
3 0/1 (0.0) 1.00 0
(B) Acute rectal toxicity (0-3 months)
RWI Number of patients (%) P value a Maximum CTCAE grade
0 36/140 (25.7) NA 2
1 3/5 (60.0) .12 1
2 1/3 (33.3) 1.00 1
3 0/1 (0.0) 1.00 0
(C) Late rectal toxicity (3-15 mo)
RWI No. of patients (%) P value a Maximum CTCAE grade
0 2/140 (1.4) NA 1
1 1/5 (20.0) .10 1
2 0/3 (0.0) 1.00 0
3 0/1 (0.0) 1.00 0
AEs, adverse events; CTCAE, Common Terminology Criteria for Adverse Events; NA, not available; RWI, rectal wall infiltration.
a Relative to RWI = 0.
b AE description: urinary track obstruction.
c Hospitalization resulting from postanesthesia tachycardia.
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controlled trial also showed that physicians placing hydrogels
found the procedure to be straightforward and achieved a very
high placement success rate.10 This prior study, however, did
not discuss how often the hydrogel was placed asymmetri-
cally or if rectal wall infiltration had occurred. Because PEG
hydrogels are injected as liquids that polymerize in situ, there
is potential for dosimetrically suboptimal positioning or
hydrogel infiltration into the anterior rectal wall; therefore, the
rates of suboptimal distribution and RWI, and their effects on
rectal dose reduction and clinical outcomes, were investigated
in this study.
Although some spacer asymmetry occurs in approxi-
mately one-half of all treated patients, all but the most
severe asymmetry results in a significant rectal dose
reduction. In this analysis, only 2 of 149 (1.3%) patients
with ≥2 cm lateral distribution at the apex, midgland, and
base did not have a statistically significant rectal dose
reduction relative to the prespacer plans. Conversely,
98.6% (147 of 149) of treated patients were in the Sym 1
through 4 groups, all of whom had significant rectal dose
reductions from rV50 to rV80. There was significant
absolute dose reduction in the rV50 and rV60, whereas the
higher dose areas had less absolute rectal dose reduction
given the lower prespacer high-dose value and therefore
less potential for reduction. However, when comparing the
mean relative dose reduction, the rV70 and rV80 volumes
have superior reduction than the lower doses. This relative
reduction in the high-dose region is likely responsible for
the decreased patient-reported rectal toxicity, which is
consistent with the literature that associates rectal toxicity
with the volume of high dose.13 In this study, we also
found that hydrogel was absent at either the apex and/or
base in 68% of patients; however, relative rectal dose
reduction of N25% in both the low- and high-dose volumes
was still appreciated in N95% of cases and is not likely
associated with incomplete spacing at these locations.
In the US Pivotal Trial, 2 primary endpoints were
defined as1 a primary effectiveness endpoint investigating
the proportion of patients achieving≥25% reduction in the
rectal volume receiving at least 70 Gy because of spacer
placement and2 a primary safety endpoint to determine the
proportion of spacer and control patients experiencing
grade 1 or greater or procedural events in the first 6 months
following treatment.10 The study concluded that more than
97.3% of spacer patients experienced a≥25% reduction in
rV70 Gy, resulting in attainment of the primary effective-
ness endpoint.7,10 When correlated with spacer symmetry,
the 2.7% (4 patients) that did not achieve a 25% reduction
of rV70Gy had Sym scores ranging from 3 to 5 and all
patients with Sym scores 1/2 met the primary effectiveness
endpoint. This may indicate that, in the scenario of
asymmetrical spacer placement (ie, Sym groups 3-5), the
likelihood of rV70 reduction of 25% may be less common;
however, the greater majority (N95%) of patients with
asymmetrical placement still achieved this reduction.
Additionally, some amount of hydrogel RWI occurred
in 9 (6.0%) patients, although no correlations were
observed between RWI and procedure-related adverse
events or with acute or late rectal toxicity. Regarding
mechanisms of imperfect distribution, asymmetric hydro-
gel positioning could be related to anatomical factors such
as fibrosis, or more frequently because of the spacer
placement learning curve. Pinkawa et al performed 64
consecutive hydrogel spacer applications and demonstrat-
ed significantly improved dosimetric benefit in the last 32
patients relative to the first 32; the rectum volume was
entirely excluded from the PTV volume in 31% of the first
32 patients compared with 56% of the second 32 patients
(P = .04).14 Furthermore, spacer symmetry was improved
after the first 15 patients; the latter 49 patients had mean
differences between right and left placement at the
midgland of 0.6 cm versus 0.3 cm (P = .03) Spacer
thickness was also improved between the first 15 patients
and the following 49 patients.14
Hydrogel RWI may also be related to the application
technique, although this has not been studied to date.
Potential mechanisms for hydrogel RWI include direct
injection into the rectal wall, as was observed in the
hydrogel spacer prospective, nonrandomized, multicenter,
single-arm, open-label European clinical trial.15 Proce-
dural improvements since that time included the use of a
side fire transrectal ultrasound probe, stabilizer/stepper,
Figure 4 T2-weighted magnetic resonance imaging scans of patients with varying amounts of hydrogel rectal wall infiltration.
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and hydrodissection in the midgland perirectal fat layer,
which have improved hydrogel distribution. Additionally,
excess hydrodissection volumes could in theory disrupt
the outer rectal wall layers allowing entry of the PEG
hydrogel liquid precursors before they polymerize.
Reducing the volume of injected spacer could also
potentially decrease RWI by minimizing rectal wall stress;
the use of stool softeners could also possibly reduce
stool-induced stress from bowel contents. One limitation
of this study is that spacer placement was supervised by
trained professionals and might be more accurate than
real-world placement by unsupervised physicians. As with
any technical procedure, however, the placement of
hydrogels is likely to improve with experience. This
study depicts results from physicians in the initial training
phase of placing the hydrogels. Additional studies will be
needed to better understand the effects of technique for
optimal hydrogel symmetry and avoidance of RWI.
Conclusion
As previously demonstrated in the SpaceOAR System
pivotal study, hydrogel placement is a safe method to
displace the rectal wall away from the prostate in men
undergoing IG-IMRT for low- to intermediate-risk
prostate cancer.10 The additional separation between
these structures significantly reduced rectal dose, which
likely correlates with decreased rectal toxicity. In this
study, asymmetry of hydrogel was found to be common;
however, all but the most extreme asymmetry still resulted
in significant rectal dose reductions. Additionally, rare
RWI was observed but was not correlated with patient
complications.
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